Skip to main content
Premium Trial:

Request an Annual Quote

Univ. of Amsterdam, GeneGo Team on Metabolic Diseases Project

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The University of Amsterdam will work with GeneGo through the company's MetaMiner Metabolic Diseases project, GeneGo said today.

The MetaMiner program is aimed at studying human diseases by using 'omics data to study disease pathways and gene-disease associations, the company said.

Through the multi-year MetaMiner programs, GeneGo develops content and tools while members, such as the University of Amsterdam or pharmaceutical companies, direct the process, prioritize goals, and edit the disease pathways. Current MetaMiner projects include collaborations in oncology, cystic fibrosis, cardiovascular diseases, and stem cells.

Milka Sokolovic at the Academic Medical Center at the University of Amsterdam said in a statement that GeneGo's disease pathway reconstructions are "fundamentally important and required for the understanding of disease processes so we can find cures."

"This will be the first 'systems analysis' platform devoted specifically for metabolic diseases," GeneGo VP of Business Development Julie Bryant said in a statement. "We will start with the 'usual suspects' of type 2 diabetes and obesity and then move to other human diseases which significantly affect metabolism."

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.